# CaboPoint (NCT03945773)

> Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03945773
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Ipsen
- Conditions: Locally Advanced or Metastatic Renal Cell Carcinoma
- Interventions: Cabozantinib
- Enrollment: 127
- Primary outcome: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review

## Commentary we found

- X threads: 20
- YouTube: 8
- Podcasts: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=cabopoint-nct03945773

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03945773", "email": "<work email>"}; the inbox owner confirms by the emailed link.